<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109317</url>
  </required_header>
  <id_info>
    <org_study_id>ACD2600g</org_study_id>
    <nct_id>NCT00109317</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy</brief_title>
  <official_title>A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled,
      multicenter study designed to evaluate the safety and tolerability of efalizumab administered
      subcutaneously at weekly doses of 1.0 mg/kg in subjects with moderate to severe plaque
      psoriasis who are candidates for systemic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">686</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva (efalizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Plaque psoriasis covering &gt;=10% of total BSA

          -  Diagnosis of plaque psoriasis for at least 6 months

          -  Minimal PASI score of 12.0 at screening

          -  In the opinion of the investigator, candidate for systemic therapy for psoriasis who
             has not been previously treated (naive to systemic treatment) or prior treatment with
             systemic therapy for psoriasis (e.g., PUVA, cyclosporine, corticosteroids,
             methotrexate, oral retinoids, MMF, thioguanine, hydroxyurea, sirolimus, azathioprine,
             6-MP, etanercept)

          -  Body weight of &lt;=140 kg

          -  18 to 75 years old

          -  For women of childbearing potential, willingness to use an acceptable method of
             contraception to prevent pregnancy for the duration of the study

          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning
             booths or other UV light sources during the study

          -  Willingness to enter Study ACD2601g

        Exclusion Criteria:

          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis

          -  History of severe allergic or anaphylactic reactions to humanized monoclonal
             antibodies or fusion proteins that contain an Ig Fc region

          -  Clinically significant psoriasis flare during screening or on the day of randomization

          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial
             infection

          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)

          -  Seropositivity for human immunodeficiency virus (HIV)

          -  Pregnancy or lactation

          -  WBC count &lt;4000/uL or &gt;14,000/uL

          -  Seropositivity for hepatitis B or C virus

          -  Hepatic enzymes &gt;=3x the upper limits of normal (ULN)

          -  History of active tuberculosis (TB) or currently undergoing treatment for TB

          -  Presence of malignancy within the past 5 years, including lymphoproliferative
             disorders

          -  Previous treatment with efalizumab (anti-CD11a)

          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity

          -  Serum creatinine &gt;=2x the ULN

          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last
             year

          -  History of substance abuse within the last 5 years

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             subject's safety following exposure to study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2005</study_first_submitted>
  <study_first_submitted_qc>April 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2005</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Plaque Psoriasis</keyword>
  <keyword>Severe Plaque Psoriasis</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

